The FDA accepted an application for ivonescimab with chemotherapy for patients with lung cancer driven by EGFR changes after ...
The FDA accepted the BLA for ivonescimab plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer post-TKI ...
Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...
Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...
To conclude our interview with Joshua K. Sabari, MD, which focused on the approval of amivantamab plus lazertinib in the first line, he looks ahead to potential uses that could help to overcome ...
In a media release on Jan. 22, it was revealed that a group of scientists from the Agency for Science, Technology and ...
Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Yeah, so the EGFR mutation lung cancer ...
Could a daily pill after chemoradiation keep lung cancer from returning? The News On 6 weekend team provides a comprehensive look at updated news events, a detailed and up-to-the-minute weather ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results